ACC pipeline
Response and survival, trial by trial.
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
1 arm has a reported figure in this set.
VEGFR TKI 1
Axitinib 5 mg twice daily
5 mg · ITT
R/M ACC with progression within 9 months (n = 60 total)
Comparator: observation
progression-free survival hazard ratio vs observation: 0.25 HR, as reported in ESMO-EURACAN guideline
Axitinib vs observation (randomized Phase 2) · NCT02859012
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.